The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma

Melanoma Research

Volumn 22, Issue 1, 2012, Pages 92-95

  Barr, Jodie ^a   Amato, Carol M ^b   Robinson, Steven E ^b   Kounalakis, Nicole ^b   Robinson, William A ^b  

^a Exempla Saint Joseph Hospital   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

desmoplastic melanoma; G691S; germline; polymorphism; RET

Indexed keywords

CELL DNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PROTEIN RET;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; DESMOSOME; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GERM LINE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; NEUROFIBROMATOSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-RET; SKIN NEOPLASMS;

EID: 84855803245     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834defd6     Document Type: Article

References (20)

1. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978; 42:660-668. (Pubitemid 8405861)
2. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
3. Dupin E, Le Douarin NM. Development of melanocyte precursors from the vertebrate neural crest. Oncogene 2003; 22:3016-3023. (Pubitemid 36713751)
4. Reed RJ, Leonard DD. Neurotropic melanoma. A variant of desmoplastic melanoma. Am J Surg Pathol 1979; 3:301-311.
5. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle-cell malignant melanoma. An immunohistochemical study. Am J Surg Pathol 1996; 20:1489-1500. (Pubitemid 26411717)
6. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998; 83:1128-1135. (Pubitemid 28419065)
7. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants A study of 45 cases. . Am J Surg Pathol 1989; 13:358-373. (Pubitemid 19134066)
8. Airaksinen MS, Holm L, Hatinen T. Evolution of the GDNF family ligands and receptors. Brain Behav Evol 2006; 68:181-190. (Pubitemid 44221721)
9. Ibanez CF. Beyond the cell surface: new mechanisms of receptor function. Biochem Biophys Res Commun 2010; 396:24-27.
10. Avantaggiato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, et al. Developmental expression of the RET protooncogene. Cell Growth Differ 1994; 5:305-311. (Pubitemid 24251380)
11. Castellone MD, Santoro M, Dysregulated RET. signaling in thyroid cancer. Endocrinol Metab Clin North Am 2008; 37:363-374, viii.. (Pubitemid 351698089)
12. Lai AZ, Gujral TS, Mulligan LM. RET signaling in endocrine tumors: delving deeper into molecular mechanisms. Endocr Pathol 2007; 18:57-67. (Pubitemid 47574988)
13. Murakumo Y, Jijiwa M, Asai N, Ichihara M, Takahashi M. RET and neuroendocrine tumors. Pituitary 2006; 9:179-192. (Pubitemid 44742279)
14. Santoro M, Carlomagno F, Melillo RM, Fusco A. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 2004; 61:2954-2964. (Pubitemid 40104593)
15. Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004; 89:3579-3584. (Pubitemid 38951937)
16. Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ, et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factorinduced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005; 65:11536-11544. (Pubitemid 41821712)
17. Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, Arigami T, et al. Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009; 28:3058-3068.
18. National Center for Biotechnology Information, N. Entrez SNP: single nucleotide polymorphism. Available at http://www.ncbi.nlm.nih.gov/projects/ SNP. [Accessed 12 August 2010].
19. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 2007; 282:29230-29240. (Pubitemid 350043334)
20. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009; 27:2823-2830.